Insulin resistance and hyperinsulinemia as risk factors for cardiovascular disease;Insulinorresistencia e hiperinsulinemia como factores de riesgo para enfermedad cardiovascular

Archivos Venezolanos de Farmacologia y Terapeutica

Volumn 27, Issue 1, 2008, Pages 30-40

  Rojas, Joselyn ^a   Bermúdez, Valmore ^a   Leal, Elliuz ^a   Cano, Raquel ^a   Luti, Yettana ^a   Acosta, Luis ^a   Finol, Freddy ^a   Aparicio, Daniel ^a   Arraiz, Nailet ^a   Linares, Sergia ^a   Rojas, Edward ^a   Canelón, Roger ^a   Deisiree, Sánchez ^a  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

Author keywords

Cardiovascular disease; Hiperinsulinemia; Insulin; Insulin resistance

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VERY LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CONFERENCE PAPER; DYSLIPIDEMIA; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE WORK; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY;

EID: 55349126101     PISSN: 07980264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (97)

1. Williams, B. "Insulin resistance: the shape of things to come". Lancet 1994; 344:521-524.
2. Himsworth, H. "Diabetes Mellitus: its differentiation into insulin-sensitive and insulin-insensitive types". Lancet 1936; 1:127-130.
3. Luo R, et al. "Quaternary structure of the Insulin-Insulin Receptor Complex". Science 1999;283:1077-1080
4. White, M. "The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action". Rescent Prog Horm Res 1998; 53:119-138.
5. Cheatham B, Kahn C. "Insulin action and the insulin signaling network", Endocr Rev 1995; 16:117-142.
6. Le Roith, D, Zick Y. "Recent advances in our understanding of insulin action and insulin resistance". Diabetes Care 2001; 24:588-597.
7. Pearson G, et al. "Mitogen Activated Proteins (MAP) kinase pathways: regulation and physiological functions" .Endocrin Rev 2001;22(2):153-183.
8. Kusari A, et al. "Insulin-Induced Mitogen-Activated Protein (MAP) Kinase Phosphatase-1 (MKP-1) Attenuates Insulin-Stimulated MAP Kinase Activity: A Mechanism for the Feedback Inhibition of Insulin Signaling". Mol Endocrinol 1997;11(10):1532-1543.
9. Sadagurski M, Weingarten G, "Insulin Receptor Substrate 2 Plays Diverse Cell-specific Roles in the Regulation of Glucose Transport" J Biol Chem 2005; 280:14536-14544.
10. Wang Q, Bilan P, Klip A. "Opposite effects of insulin on focal adhesion proteins in 3T3-L1 adipocytes and in cells overexpressing the insulin receptor". Mol Biol Cell 1998;9(11):3057-3069.
11. WHO Nutrition Data Banks Global Database on Obesity and Body Mass Index (BMI) in Adults.http://www.who.int/nut/db_bmi.htm
12. Wajchenberg, B L. "Subcutaneos and Visceral Adipose Tissue: their relationship to the Metabolic Syndrome". Endocrine Reviews 2000;21(6):697-738.
13. Hill, J O; Peters, J C. "Environmental Contributions to the Obesity Epidemic". Science 1998; 280; 5368; 1371-1374
14. Bjorntorp, P. "The association between obesity, adipose tissue distribution and disease". Acta Med Scand Suppl. 1988; 723: 121-134.
15. Derpress, J P. "Abdominal obesity an important component of insulin resistance syndrome". Nutrition 1999; 9:452-459.
16. Koyama, K: Chen, G; Lee, Y; Unger, R. "Tissue Triglycerides, insulin resistance and insulin production: implications for hyperinsulinemia of obesity". Am J. Physiol Endrocrinol Metab 1997;273:E708-E713.
17. Kahn B B; Flier, J S. "Obesity and Insulin Resistance". J Clin Invest 2000;106(4):473-481.
18. Koska J, Ortega E. "The effect of insulin on net lipid oxidation predicts worsening of insulin resistance and development of type 2 diabetes mellitus". Am J Physiol Endocrinol Metab 2007; 293: E264-E269
19. Roden M, et al. "Mechanism of free fatty acids-induced insulin resistance in humans". J Clin Invest 1996; 97:2859-2865.
20. Griffin M, et al. "Free fatty induced insulin resistance is associated with activity of protein kinase C theta and alterations in the insulin signaling cascade". Diabetes 1999; 48:1270-1274.
21. Shulman, G. "Cellular mechanism of insulin resistance". J Clin Invest 2000; 102(2):171-176.
22. Stein D, et al. "The Insulinotropic Potency of Fatty Acids Is Influenced Profoundly by Their Chain Length and Degree of Saturation". J Clin Invest 1997; 100(2):398-403.
23. Hotamisligil G, Spiegelman B. "Adipose expression of tumoral necrosis factor á: direct role in obesity-linked insulin resistance". Science 1993; 259:87-91.
24. Qi C, Pekala P. "Tumor necrosis factor-α-induced insulin resistance in adipocytes". P.S.E.B.M 2000; 233:128-135.
25. Kieffer TJ; Habener, JF. The adipoinsular axis; effects of leptin on pancreatic ácell. Am J Physiol Endocrinol Metab. 2000;278:E1-E14.2000.
26. Taylor S, Barr V, Reitman M. "Does leptin contribute to diabetes caused by obesity?". Science 1996; 274(5290):1151-0.
27. Emilsson V, et al. "Hexosamines and Nutrient Excess Induce Leptin Production and Leptin Receptor Activation in Pancreatic Islets and Clonal ß-Cells". Endocrinology 2001;142(10):4414-4419.
28. Hebert L, et al. "Overexpression of Glutamine:Fructose-6-Phosphate Aminotransferase in Transgenic Mice Leads to Insulin Resistance" J Clin Invest 1996;98(4):930-936.
29. Virkamäki A, et al. "Activation of the Hexosamine Pathway by Glucosamine in Vivo Induces Insulin Resistance in Multiple Insulin Sensitive Tissues" . Endocrinology 1997;138(6):2501-2507.
30. Vossller K, et al. "Elevated nucleocytoplasmic glycosylation by O-GlcNAc results in insulin resistance associated with defects in Akt activation in 3T3-L1 adipocytes". Proc Natl Acad Sci USA 2002;99(8):5313-5318.
31. Reaven G, Hoffman B. "A role for insulin in the a etiology and course of hypertension?" Lancet 1987;11:435-37.
32. Saad M; Rewers M, et al. "Insulin Resistance and Hypertension". Hypertension. 2004;43:1324.
33. Kotchen TA, Zhang HY, Covelli M, Blehschmidt N. "Insulin resistance and blood pressure in Dahl rats and in one-kidney, one-clip hypertensive rats". Am J Physiol 1991;261:E692-E697.
34. Reaven GM, Chang H. "Relationship between blood pressure, plasma insulin and triglyceride concentration, and insulin action in SHR and WKY rats". Am J Hypertens. 1991;4:34-38
35. Standley PR, Ram JL, Sowers JR. "Insulin attenuation of vasopressin-induced calcium responses in arterial smooth muscle from Zucker rats". Endocrinology. 1993;133:1693-1699
36. P. L. Hofman, F. Regan, Et all. "Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin". J. Clin. Invest., 2004; 114(5): 652 - 658.
37. Mancia G, Grassi G, Giannattasio C, Seravalle G. "Sympathetic activation in the pathogenesis of hypertension and progression of organ damage". Hypertension 1999;34[part 2]:724-728.
38. Margolis RU, Altszuler N. "Insulin in the cerebrovascular fluid". Nature. 1967;215:1375-1376.
39. Muntzel MS, Morgan DA, Mark AL, Johnson AK. "Intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity". Am J Physiol. 1994;267:R1350-R1355.
40. Vollenweider P, Randin D, Tappy L, Jéquier E, Nicod P, Scherrer U. "Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans". J Clin Invest. 1994;93:2365-2371.
41. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. "Body fat and sympathetic nerve activity in healthy subjects". Circulation. 1994;89:2634-2640.
42. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. "Sympathetic activation in obese normotensive subjects". Hypertension. 1995;25[part 1]:560-563.
43. Verma S, Bhanot S, Yao L, McNeill J. "Defective endothelium- dependent relaxation in fructose-fed hypertensive rats". Am J Hypertens 1996;9:370-376.
44. Campbell W, et al. "Identification os epoxyeicosatrienoic acid as endothelium derived hyperpolarizing factors". Circulation Research 1996; 78:415-423
45. J. H. Capdevila, J. R. Falck, and R. C. Harris. "Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase". J.Lipid Res.2000;41:163 181.
46. Miller A, et al. "Epoxyeicosatrienoic acid-induced relaxation is impaired in insulin resistance". AJP-Heart Cir Physiol. 2001;281(4):H1524-H1531.
47. Katakam P, Ujhelyi M, Miller A. "EDHF mediated relaxation is impaired in fructose fed rats". J Cardiovasc Pharmacol 1999;34:461-467.
48. Miller A, Hoenig M, Ujhelyi M. "mechanism of impaired endothelial function associated with insulin resistance. J Cardiovasc Pharmacol 1998;3:125-134.
49. McFarlane S, Banerji M, Sowers J. "Insulin resistance and cardiovascular disease". J Ckin Endocrin & Metab. 2001; 86(2):2713-2718.
50. Sowers J. "Insulin and IGF in normal and pathological cardiovascular physiology". Hypertension 1997; 29:691-699.
51. Sowers JR. "Effects of insulin and IGF-1 on vascular smooth muscle glucose and cation metabolism". Diabetes. 1996;45:47-51.
52. Chambers et al. "Serum Magnesium and Type-2 Diabetes in African Americans and Hispanics: A New York Cohort". J. Am. Coll. Nutr. 2006;25:509-513.
53. Dominguez L, Sowers J, Barbagallo M, Resnick L. "Magnesium responsiveness to insulin and IGF-1 in erythrocytes from normotensives and hypertensive subjects". J Clin Endocrin Metab 1998;83(12):4402-4407.
54. Zeng G, "Roles for insulin receptor, PI3-kinase, and Akt in insulin-signaling pathways related to production of nitric oxide un human vascular endothelial cells". Circulation 2000;101:1539-1545.
55. McKay M, Hester R. "Role of nitric oxide, adenosine, and ATP sensitive potassium channels in insulin-induced vasodilation" Hypertension. 1996;28:202-208.
56. Schiffrin E. "Role of Endothelin-1 in hypertension". Hypertension, 1999; 34[part 2]:876-881.
57. Irving R, et al. "Activation of the endothelin system in insulin resistance". Q J Med. 2001;94:321-326.
58. Katakam P, Pollock J, Pollock D, Ujhelyi M, Miller A. "Enhanced endothelin-1 response and receptor expression in small mesenteric arteries of insulin-resistance rats". AJP - Heart Cir Physiol. 2001;280(2):H522-H527.
59. Brands M, et al. "Insulin-induced hypertension in rats depends on an intact rennin-angiotensin system". Hypertension. 1997;29:1014-1019.
60. Rocchini AP, Moorehead C, DeRemer S, Goodfriend TL, Ball DL. "Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II". Hypertension. 1990;15:861-866.
61. Zemel MB, Peuler JD, Sowers JR. "Hypertension in insulin-resistant Zucker obese rats is independent of sympathetic neural support". Am J Physiol. 1992;262:E368-E371.
62. Ferri C, et al. "Relationship between insulin resistance and non-modulating hypertension. Linkage of metabolic anormalities and cardiovascular risk". Diabetes 1999;48:1623-1630.
63. Doria A, Fiotetto P, Avogaro A. "Insulin resistance is associated with high sodium-lithium countertransport in esscential hypertension". Am J Physiol 1991;261:E684-E691.
64. + currents in adult mouse ventricular myocytes". J Gen Physiol 1999;113:661-677.
65. + currents". AJP- Heart Cir Physiol. 2000; 279(2);H639-H649.
66. Bermúdez-Arias, F. "Electrocardiografía diagnóstica". Editorial McGraw-Hill Interamericana de Venezuela. Caracas 2000, pp 64-36.
67. Watanabe T, Ashikaga T, et al. "Association of insulin with QTc dispersion". Lancet 1997;350:1821-1822.
68. Viskin S. "Long QT syndromes and torsade de pointes". Lancet 1999 ;354 :1625.
69. Stary H, Chandler A, Sisismore R, et al. "A definition of advanced type of atherosclerotic lesions and a histological classification of atherosclerosis. Classification of atherosclerosis. A report from the Committee on Vascular Lesion of the Council on Atherosclerosis. AHA". Circulation 1995;92:1355-1374.
70. Fuster V, Fayad Z, Badimon J. "Acute coronary syndromes: biology". Lancet 1999;353(suppl II):5-9.
71. Howard G, et al. "Insulin Sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study". Circulation. 1996;93:1809-1817.
72. Zammit V, Waterman I, Topping D, McKay G. "Insulin stimulating of hepatic triacylglycerol secretion and the etiology of insulin resistance". J Nutr 2001;131:2074-2077.
73. Ginsberg H. "Insulin resistance and cardiovascular disease". J Clin Invest.2000; 106(4):453-458.
74. Durand P, Prost M, Loreau N, et al. "Impared homocysteine metabolism and atherotrombotic disease". Lab Invest 2001;81:645-672.
75. Meigs J, et al. "Fasting plasma homocysteine levels in the insulin resistance syndrome. The Framingham Offspring Study". Diabetes Care. 2001; 24:1403-1410.
76. Lang D, et al. "Homocystein-induced inhibition of endothelium-dependent relaxation in rabbit aorta". Art Thromb Vasc Biol 2000;20:422.
77. Banfi C, et al. "Transcriptional regulation of plasminogen activator inhibitor type 1 gen by insulin". Diabetes 2001;50:1522-1530.
78. Abbasi F, et al. "Comparison of Plasminogen Activator Inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women". Arterios Thromb Vasc Biol. 1999;19:2818.
79. Juhan-Vague I, Alessi M. "PAI-1, obesity, insulin resistance and cardiovascular events". Thromb Haemost 1997;78:656-660.
80. Válek J, et al. "Increased fibrinogen levels in the offspring of hypertensive men. Relation with Hyperinsulinemia and the metabolic syndrome". Art Thromb Vasc Biol 1995:15:2229-2233.
81. Lagrand W, et al. "C-Reactive protein as a cardiovascular factor. More than an epiphenomenon?". Circulation 1999;100:96-102.
82. Festa A, et al. "Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study". Circulation 2000;102:42.
83. Westerbacka J, et al. "Inhibition of platelet-collagen interaction. An in vivo action of insulin abolished by insulin resistance in obesity", Art Thromb Vasc Biol 2002;22:167.
84. Russell R, et al. "Additive effects of hiperinsulinemia and ischemia on myocardial GLUT1 and GLUT4 translocation in vivo". Circulation 1999;98:2180-2186.
85. Heusch G. "Hibernating myocardium". Physiol rev 1998;78(4):1055-1085
86. Gamici P, et al. "Pathophysiological mechanisms of chronica reversible left ventricular dysfunction due to coronary artery disease (hibernating myocardium)". Circulation 1997:96:3205-3214
87. transportadores de glucose.
88. Zelzer E, Levy Y, et al. "Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-1á/ARNT". EMBO 1998;17:5085-5094
89. Iozzo P, et al. "Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance". Diabetes. 2002;51:3020-3024.
90. Diaz R, Paolasso E, et al. "Metabolic modulation of acute myocardial infarction. The ECLA Glucose-Insulin-Potassium pilot trial". Circulation 1998;98:2227-2234.
91. Sacco R. "Identifying patient populations at high risk for stroke". Neurology 1998;51(Suppl 3):S27.
92. Shinozaki K, et al. "Role of insulin resistance with compensatory hiperinsulinemia in ischemic stroke". Stroke 1997;27:37-43.
93. Erdos B, et al. "Alterations in calcium-activated and ATP-dependent potassium channel function in cerebral arteries of insulin resistant rats". AJP-Heart Cir Physiol 2002;10:1152.
94. Swynghedanw, B. "Molecular mechanisms of myocardial remodeling". Physiol rev 1999;79(1):215-262.
95. Weber T, Brilla C, Janicki J. "Myocardial fibrosis : its functional significance and regulating factors". Cardiovasc Res 1993;27:341-348.
96. McNulty P, et al. "Hyperinsulinemia inhibits myocardial protein degradation in patients with cardiovascular disease and insulin resistance". Circulation 1995;92:2151-2156.
97. Abel ED, Kaulbach H, et al. "Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart". J Clin Invest 1999;104:1703-714.